Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Other Non-Current Assets (2016 - 2022)

Aptevo Therapeutics' Other Non-Current Assets history spans 8 years, with the latest figure at $427000.0 for Q3 2022.

  • For Q3 2022, Other Non-Current Assets fell 42.76% year-over-year to $427000.0; the TTM value through Sep 2022 reached $427000.0, down 42.76%, while the annual FY2021 figure was $1.3 million, 50.72% down from the prior year.
  • Other Non-Current Assets for Q3 2022 was $427000.0 at Aptevo Therapeutics, down from $546000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $12.4 million in Q2 2018 and bottomed at $25000.0 in Q3 2018.
  • The 5-year median for Other Non-Current Assets is $905000.0 (2018), against an average of $1.9 million.
  • The largest annual shift saw Other Non-Current Assets tumbled 99.23% in 2018 before it surged 13456.0% in 2019.
  • A 5-year view of Other Non-Current Assets shows it stood at $905000.0 in 2018, then skyrocketed by 320.11% to $3.8 million in 2019, then crashed by 32.8% to $2.6 million in 2020, then plummeted by 50.72% to $1.3 million in 2021, then plummeted by 66.08% to $427000.0 in 2022.
  • Per Business Quant, the three most recent readings for APVO's Other Non-Current Assets are $427000.0 (Q3 2022), $546000.0 (Q2 2022), and $1.3 million (Q1 2022).